The pathological excess of fibroblast growth factor 23 (FGF23) causes mineral disorders and bones. However, the causality of the FGF23 in the development of osteoporosis remains unknown. If FGF23 has systemic effects on cardiometabolic disorders beyond the regulation of mining metabolism is also controversial. In this study, we studied the causal effect of FGF23 on osteoporosis and cardiometabolic disorders using the mendelian randomization analysis (MR). Summary statistics for monocleotide polymorphisms with interest features were obtained from the genome-wide association studies.
As a result, the FGF23 was judged inversely associated with the femoral BMD and the BMD (EBMD) heel (EBMD) of the reverse-variance analysis, but not from the lumbar-bmd spine and fractures. The results were supported by the weighted median analysis and there was no evidence of the pleiotropy in the MR-Egger analysis. FGF23 has been associated with the FN-BMD and EBMD after adjustment of the estimated glomerular filtration index, height and body mass index in a Mr multivariable analysis.
On the other hand, there was no association between the FGF23 and cardiometabolic features, including cardio artery disease, the speed of the pulse wave of the brachial-hop, the thickness of the respondent carotid of Carotid arteries, systolic and diastolic blood pressure, fasting glucose, high and low density and triglyceride lipoprotein cholesterol. Therefore, this study found that the FGF23 was involved in bone loss and, on the other hand, was not involved in cardiometabolic disorders. Our conclusions provide important information on the role of FGF23 in the pathogenesis of osteoporosis and cardiometabolic disorders.
Roles for fibroblast growth factor-23 and α-klotho in an acute kidney injury
An acute renal injury is a global disease with high morbidity and mortality. Recent studies have revealed that the Fibroblast-23-α-Klotho growth factor axis is closely linked to chronic renal disease and has multiple biological functions beyond the metabolism of OS-minerals. However, although the dysregulation of the fibroblast-23-α-klotho growth factor has been observed in an acute kidney injury, the role of the growth factor of fibroblast-23-α-klotho in the pathophysiology of wounds with Acute kidneys remains largely unknown. In this review, we describe recent conclusions on the growth factor for fibroblast-23-α-klotho, which is mainly involved in inflammation, oxidative stress and hemodynamic disorders. In addition, on the basis of these recent results, we have submitted new information about the relationship between the growth factor of Fibroblast-23-α-Klotho axis and an acute relent injury, which can provide new therapeutic targets.
To treat injuries with acute renal. Currently, insulin is commonly used in the clinical management of canine diabetes. However, it must be injected precondally, causing many disadvantages for the owners. Therefore, the development of prolonged hypoglycemic agents has drawn a lot of attention to the scientific community. This study aimed to investigate the prolonged hypoglycemic effect of the Canine 21 Fibroblast Growth Factor (CFGF-21) in diabetic dogs. Diabetic dogs were administered with the CFGF-21, the CFGF-21 modified by polyethylene glycol or insulin once a day, once every 2, 3 or 4 days subcutaneously. The results showed that CFGF-21 and PEG-CFGF-21 maintain blood sugar comparable to normal levels for 2 and 3 days, respectively, while insulin maintained blood glucose for only 2 hours after a single injection. After treatment with the CFGF-21, the oral glucose tolerance test (OGTT) has been considerably improved with glycosylated hemoglobin (HBA1C) near normal levels.
Investigating the causal effect of fibroblast growth factor 23 on osteoporosis and cardiometabolic disorders: A Mendelian randomization study
The growth factor of retinoic acid and fibroblast play a key role on the modulation of sex hormones and apoptosis in a polycystic ovarian syndrome mouse model induced by Estradiol Valthenes
Objective: The main objective of this study is to study the effects of retinoic acid and Fabroblast Factor-2 on serum levels of FSH and LH, histology and apoptosis in the mouse model Ovarian polycytic polydrome (PCO).
Materials and methods: 80 feminine NMRI mice were randomly divided into eight groups. Group 1 received normal saline as control and group 2 received from Estradiol Valthe (EV) at 4 mg / 100 g body weight. In addition, the groups 3-4 were administered with Ra (a dose of 0.05 μg / μl) and FGF2 (a dose of 0.01 μg / kg), respectively. The groups 5 and 6 have respectively received the EV plus the Ra (0.05 μg / μl) and the FGF2 (0.01 μg / kg). Group 7 received the RA and the FGF2 at doses corresponding to healthy mice and group 8 received the EV plus the RA + FGF2 (similar to the previous doses). RA and FGF2 have been injected three times a week for four weeks. Finally, the histological and immunohistological parameters of the ovary have been evaluated.
Results: The study revealed that the unique and combination injection of FIBROblast injection factor-2 (FGF2) and retinoic acid (RA) in groups 5, 6 and 8 significantly reduces comparative follicular diameters To the group 2. The measurements confirmed this simultaneous injection of RA and FGF2 in polycystic mouse increased the antral follicles, the corpus stutter (CL), the epithelial thickness and the diameter of the oocytes as well as reduced cystic follicles. The positive tunel cells that have been considerably increased in group 2 antiter follicle have decreased considerably in RA and FGF2 recipient groups, only or in combination. In addition, the injection of FGF2 has increased notice follicles and cl.
Description: Recombinant human aFGF (acidic Fibroblast Growth Factor) is a disulfide-linked monomer protein consisting of 141 a.a. and migrates as an approximately 16 kDa protein under reducing and non-reducing conditions. Native human aFGF, generated by the proteolytic removal of the signal peptide and propeptide, has a calculated mass of 16 kDa. Optimized DNA sequence encoding human acidic Fibroblast Growth Factor mature chain was expressed in E. coli.
Description: Recombinant human aFGF (acidic Fibroblast Growth Factor) is a disulfide-linked monomer protein consisting of 141 a.a. and migrates as an approximately 16 kDa protein under reducing and non-reducing conditions. Native human aFGF, generated by the proteolytic removal of the signal peptide and propeptide, has a calculated mass of 16 kDa. Optimized DNA sequence encoding human acidic Fibroblast Growth Factor mature chain was expressed in E. coli.
Description: Recombinant murine aFGF (acidic Fibroblast Growth Factor) is a disulfide-linked monomer protein consisting of 141 a.a. and migrates as an approximately 16 kDa protein under reducing and non-reducing conditions. Native murine aFGF, generated by the proteolytic removal of the signal peptide and propeptide, has a calculated mass of 16 kDa. Optimized DNA sequence encoding murine acidic Fibroblast Growth Factor mature chain was expressed in E. coli.
Description: Recombinant murine aFGF (acidic Fibroblast Growth Factor) is a disulfide-linked monomer protein consisting of 141 a.a. and migrates as an approximately 16 kDa protein under reducing and non-reducing conditions. Native murine aFGF, generated by the proteolytic removal of the signal peptide and propeptide, has a calculated mass of 16 kDa. Optimized DNA sequence encoding murine acidic Fibroblast Growth Factor mature chain was expressed in E. coli.
Description: Recombinant mouse bFGF is a disulfide-linked homodimeric protein consisting of 146 amino acid residue subunits, and migrates as an approximately 16 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Mouse basic Fibroblast Growth Factor mature chain was expressed in E. coli.
Description: Recombinant mouse bFGF is a disulfide-linked homodimeric protein consisting of 146 amino acid residue subunits, and migrates as an approximately 16 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Mouse basic Fibroblast Growth Factor mature chain was expressed in E. coli.
Description: Recombinant human FGF-10, (Fibroblast Growth Factor 10), is a disulfide-linked monomer protein consisting of 169 amino acids and migrates as an approximately 19 kDa protein under reducing and non-reducing conditions. Source: Optimized DNA sequence encoding human FGF-10 mature chain was expressed in E. coli.
Description: Recombinant human FGF-10, (Fibroblast Growth Factor 10), is a disulfide-linked monomer protein consisting of 169 amino acids and migrates as an approximately 19 kDa protein under reducing and non-reducing conditions. Source: Optimized DNA sequence encoding human FGF-10 mature chain was expressed in E. coli.
Description: Recombinant Fibroblast Growth Factor 21 is a disulfide-linked monomer protein consisting of 182 amino acid residues, and migrates as an approximately 20 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human Fibroblast Growth Factor-21 mature chain was expressed in E. coli.
Description: Recombinant Fibroblast Growth Factor 21 is a disulfide-linked monomer protein consisting of 182 amino acid residues, and migrates as an approximately 20 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human Fibroblast Growth Factor-21 mature chain was expressed in E. coli.
Description: Recombinant Fibroblast Growth Factor-9 is a disulfide-linked monomer protein consisting of 208 amino acid residues, and migrates as an approximately 23 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Description: Recombinant Fibroblast Growth Factor-9 is a disulfide-linked monomer protein consisting of 208 amino acid residues, and migrates as an approximately 23 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Conclusion: The conclusions of this survey reveal that the injection of RA and FGF2 has both protective and improvement effects that can promise new therapies for women with PCO.
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA | DNA Testing | Elisa Kits | Enzymes | Equipments | Exosomes | Gels | Isotypes | Medium & Serums | Panel | Particles | PCR | Pcr Kits | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA Templates | DNA Testing | Elisa Kits | Enzymes | Exosomes | Gels | Isotypes | Medium & Serums | Panel | Particles | PCR | Peptides | Reagents | Recombinant Proteins | Ria Kits | Test Kits | Vector & Virus 
Antibodies | Assay Kits | Biology Cells | Clia Kits | Culture Cells | Devices | DNA Templates | DNA Testing | Elisa Kits | Enzymes | Exosomes | Gels | Isotypes | NATtrol | Panel | Particles | Pcr Kits | Peptides | Reagents | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot
No Comment